Long-term Use of Eculizumab in Kidney Transplant Recipients

Sabrina Milan Manani^{1

2}, Grazia Maria Virzì^{1

2}, Claudio Ronco^{1

2}

Affiliations

¹ Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy.
² IRRIV-International Renal Research Institute, Vicenza, Italy.

Editorial

Sabrina Milan Manani et al. Kidney Int Rep. 2018.

. 2018 Dec 3;4(3):370-371.

doi: 10.1016/j.ekir.2018.10.022. eCollection 2019 Mar.

Sabrina Milan Manani^{1

2}, Grazia Maria Virzì^{1

2}, Claudio Ronco^{1

2}

¹ Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy.
² IRRIV-International Renal Research Institute, Vicenza, Italy.

No abstract available

Cited by

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.
Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Gonzalez Suarez ML, et al. J Clin Med. 2019 Jun 27;8(7):919. doi: 10.3390/jcm8070919. J Clin Med. 2019. PMID: 31252541 Free PMC article.

1. Legendre C.M., Licht C., Muus P. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181. - PubMed
1. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012;2012:617–625. - PubMed
1. Zuber J., Le Quintrec M., Krid S. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337–3354. - PubMed
1. Le Quintrec M., Zuber J., Moulin B. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663–675. - PubMed
1. Milan Manani S., Virzi G.M., Giuliani A. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron. 2017;136:245–253. - PubMed